{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:00:38Z","timestamp":1789880438692,"version":"4.0.1"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Brain volume loss (BVL) is a marker of neurodegeneration associated with clinical disability in multiple sclerosis (MS). However, its application in routine clinical practice is limited due to measurement errors introduced by the use of different magnetic resonance imaging (MRI) scanners across and within centers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To confirm the existence and clinical relevance of longitudinal BVL in a real-world MS cohort with scanner variability, employing a dedicated quantification pipeline combined with post-acquisition harmonization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed MRI data from 72 MS patients scanned across multiple Belgian centers over 48\u201360\u202fmonths. Clinical disability was assessed using the Expanded Disability Status Scale, Timed 25-Foot Walk Test, 9-Hole Peg Test (9HPT), and Symbol Digit Modalities Test. Percentage volume change (PVC) in whole brain (WB), total gray matter (TGM), cortical gray matter (CGM), and deep gray matter was quantified using the icobrain ms pipeline. A similarity index was applied to account for scanner differences. Twenty-seven healthy volunteers served as controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>No significant differences in annualized PVC were observed between MS patients and controls. Within the MS group, 9HPT performance correlated with TGM (<jats:italic>\u03c1<\/jats:italic>\u202f=\u202f\u22120.30, <jats:italic>p<\/jats:italic>\u202f=\u202f0.017) and CGM (<jats:italic>\u03c1<\/jats:italic>\u202f=\u202f\u22120.31, <jats:italic>p<\/jats:italic>\u202f=\u202f0.015) volume loss. Modified MS Functional Composite scores correlated with WB (<jats:italic>R<\/jats:italic>\u202f=\u202f0.28, <jats:italic>p<\/jats:italic>\u202f=\u202f0.03), TGM (<jats:italic>\u03c1<\/jats:italic>\u202f=\u202f0.31, <jats:italic>p<\/jats:italic>\u202f=\u202f0.014), and CGM (<jats:italic>\u03c1<\/jats:italic>\u202f=\u202f0.31, <jats:italic>p<\/jats:italic>\u202f=\u202f0.013) volume loss and could be independently predicted by these measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using automated brain volumetry with post-acquisition harmonization to address scanner variability, we did not detect accelerated BVL in this real-world MS cohort compared to healthy individuals. Nonetheless, GM volume loss was found to be clinically relevant in MS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1637835","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:18:42Z","timestamp":1760588322000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world brain volumetry in multiple sclerosis: importance of methodological consistency and clinical relevance of gray matter atrophy"],"prefix":"10.3389","volume":"16","author":[{"given":"Joke","family":"Temmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Vanremoortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bjerke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie B.","family":"D\u2019Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Nagels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayla","family":"Pauwels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Sima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen Van","family":"Schependom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy M. J.","family":"Wittens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"D\u2019haeseleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ENE.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/J.AMJMED.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the \u2018real MS\u2019","author":"Hellwig","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1097\/WCO.0000000000001262","article-title":"Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold","volume":"37","author":"Krieger","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/S40263-020-00771-Z\/TABLES\/2","article-title":"Siponimod: a review in secondary progressive multiple sclerosis","volume":"34","author":"Scott","year":"2020","journal-title":"CNS Drugs"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1093\/BRAIN\/AWAC111","article-title":"Group on behalf of the IMSRC, Bellinvia a, et al. progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study","volume":"145","author":"Portaccio","year":"2022","journal-title":"Brain"},{"key":"ref7","first-page":"a028969","volume-title":"Magnetic resonance imaging in multiple sclerosis","author":"Hemond","year":"2018"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/J.NIC.2017.01.002","article-title":"Brain atrophy in multiple sclerosis: clinical relevance and technical aspects","volume":"27","author":"Sastre-Garriga","year":"2017","journal-title":"Neuroimaging Clin N Am"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13317-019-0117-5","article-title":"Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options","volume":"10","author":"Sokratous","year":"2019","journal-title":"Autoimmunity Highlights 2019 10:1"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/HBM.23168","article-title":"Postmortem validation of MRI cortical volume measurements in MS","volume":"37","author":"Voorn","year":"2016","journal-title":"Hum Brain Mapp"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1212\/WNL.0000000000011241","article-title":"Efficacy of high-intensity aerobic exercise on brain MRI measures in multiple sclerosis","volume":"96","author":"Ringgaard","year":"2021","journal-title":"Neurology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"E1027","DOI":"10.1212\/WNL.0000000000010284","article-title":"A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis","volume":"95","author":"Tansy","year":"2020","journal-title":"Neurology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/S1474-4422(19)30485-5","article-title":"Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial","volume":"19","author":"Parker","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e021944","DOI":"10.1136\/BMJOPEN-2018-021944","article-title":"Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis","volume":"8","author":"Plantone","year":"2018","journal-title":"BMJ Open"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/01.WNL.0000316810.01120.05","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis","volume":"71","author":"Minagar","year":"2008","journal-title":"Neurology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ANA.24018","article-title":"Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jnnp-2014-309903","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis","volume":"87","author":"Bartolozzi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","article-title":"2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis","volume":"20","author":"Banwell","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/S41582-020-0314-X","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Rocca","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3174\/ajnr.A5876","article-title":"Brain atrophy is associated with disability progression in patients with MS followed in a clinical routine","volume":"39","author":"Hagemeier","year":"2018","journal-title":"Am J Neuroradiol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3174\/ajnr.A6684","article-title":"Disability improvement is associated with less brain atrophy development in multiple sclerosis","volume":"41","author":"Hagemeier","year":"2020","journal-title":"Am J Neuroradiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"102554","DOI":"10.1016\/J.NICL.2020.102554","article-title":"Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes","volume":"29","author":"Ramasamy","year":"2021","journal-title":"Neuroimage Clin."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/brb3.518","article-title":"Reliable measurements of brain atrophy in individual patients with multiple sclerosis","volume":"6","author":"Cambron","year":"2016","journal-title":"Brain Behav"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Carroll","year":"2018","journal-title":"Lancet Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/1971400917721521","article-title":"Intercontinental validation of brain volume measurements using MSmetrix","volume":"31","author":"Finkelsztejn","year":"2018","journal-title":"Neuroradiol J"},{"key":"ref26","first-page":"547","article-title":"Assessing the reliability of longitudinal MRI examinations in multiple sclerosis follow-up","volume":"25","author":"Sima","year":"2019","journal-title":"Mult Scler"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"106148","DOI":"10.1016\/j.msard.2024.106148","article-title":"Utility of icobrain for brain volumetry in multiple sclerosis clinical practice","volume":"92","author":"Havrdova","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/1352458517690823","article-title":"Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis","volume":"23","author":"Phillips","year":"2017","journal-title":"Mult Scler"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/1352458517690824","article-title":"The nine-hole peg test as a manual dexterity performance measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult Scler"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1177\/1352458517690821","article-title":"Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis","volume":"23","author":"Benedict","year":"2017","journal-title":"Mult Scler"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/135245859900500409","article-title":"The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment","volume":"5","author":"Fischer","year":"1999","journal-title":"Mult Scler J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/JCM11030523","article-title":"Brain volume loss can occur at the rate of Normal aging in patients with multiple sclerosis who are free from disease activity","volume":"11","author":"Guldolf","year":"2022","journal-title":"J Clinical Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"608491","DOI":"10.3389\/FNEUR.2021.608491\/BIBTEX","article-title":"Deciphering multiple sclerosis progression","volume":"12","author":"Eichau-Madue\u00f1o","year":"2021","journal-title":"Front Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/S40263-014-0140-Z\/METRICS","article-title":"Clinical relevance of brain volume measures in multiple sclerosis","volume":"28","author":"Mattle","year":"2014","journal-title":"CNS Drugs"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1756286418823462","DOI":"10.1177\/1756286418823462","article-title":"Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration?","volume":"12","author":"Beadnall","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"109289","DOI":"10.1016\/J.COMPBIOMED.2024.109289","article-title":"Higher effect sizes for the detection of accelerated brain volume loss and disability progression in multiple sclerosis using deep-learning","volume":"183","author":"Buddenkotte","year":"2024","journal-title":"Comput Biol Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e0206939","DOI":"10.1371\/JOURNAL.PONE.0206939","article-title":"Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in multiple sclerosis using a variety of automated segmentation pipelines","volume":"13","author":"Chu","year":"2018","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"102543","DOI":"10.1016\/J.MSARD.2020.102543","article-title":"Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: a longitudinal, retrospective study","volume":"46","author":"Seidl","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1212\/01.WNL.0000055926.69643.03","article-title":"Evidence of early cortical atrophy in MS: relevance to white matter changes and disability","volume":"60","author":"Agosta","year":"2003","journal-title":"Neurology"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/BRAIN\/AWAB132","article-title":"Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement","volume":"144","author":"Arnold","year":"2021","journal-title":"Brain"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/S1474-4422(12)70230-2","article-title":"Measurement and clinical effect of grey matter pathology in multiple sclerosis","volume":"11","author":"Geurts","year":"2012","journal-title":"Lancet Neurol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1177\/1352458516629769","article-title":"A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients","volume":"22","author":"Vaneckova","year":"2016","journal-title":"Mult Scler"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/JAMANEUROL.2022.1025","article-title":"Association of Brain Atrophy with Disease Progression Independent of relapse activity in patients with relapsing multiple sclerosis","volume":"79","author":"Benkert","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ana.21436","article-title":"Gray matter atrophy in multiple sclerosis: a longitudinal study","volume":"64","author":"Fisher","year":"2008","journal-title":"Ann Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1111\/ENE.15098","article-title":"Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort","volume":"28","author":"Papadopoulou","year":"2021","journal-title":"Eur J Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/J.NICL.2017.11.002","article-title":"Gray matter atrophy patterns in multiple sclerosis: a 10-year source-based morphometry study","volume":"17","author":"Uher","year":"2018","journal-title":"Neuroimage Clin."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41380-023-01943-1","article-title":"Correspondence among gray matter atrophy and atlas-based neurotransmitter maps is clinically relevant in multiple sclerosis","volume":"28","author":"Margoni","year":"2023","journal-title":"Molecular Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ANA.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis","volume":"83","author":"Altmann","year":"2018","journal-title":"Ann Neurol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"103609","DOI":"10.1016\/J.NICL.2024.103609","article-title":"Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis","volume":"42","author":"Weinstock-Guttman","year":"2024","journal-title":"Neuroimage Clin"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1212\/WNL.0000000000200006\/ASSET\/1147B425-829E-40F9-B9FB-0B0FDB570E44\/ASSETS\/GRAPHIC\/17TTU1.GIF","article-title":"Relationship between white matter lesions and Gray matter atrophy in multiple sclerosis","volume":"98","author":"Lie","year":"2022","journal-title":"Neurology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/BRAIN\/AWR182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Carassiti","year":"2011","journal-title":"Brain"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/ANA.22230","article-title":"A gradient of neuronal loss and meningeal inflammation in multiple sclerosis","volume":"68","author":"Roncaroli","year":"2010","journal-title":"Ann Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/JAMANEUROL.2024.1961","article-title":"Acute clinical events identified as relapses with stable magnetic resonance imaging in multiple sclerosis","volume":"81","author":"Kerbrat","year":"2024","journal-title":"JAMA Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ACN3.51302","article-title":"Dynamics of pseudo-atrophy in RRMS reveals predominant gray matter compartmentalization","volume":"8","author":"Stromillo","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1212\/01.WNL.0000149516.30155.B8","article-title":"Rate of brain atrophy in relapsing MS decreases during treatment with IFN\u03b2-1a","volume":"64","author":"Fisher","year":"2005","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/BRAIN\/AWM291","article-title":"Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection","volume":"131","author":"Zeis","year":"2008","journal-title":"Brain"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3174\/AJNR.A5442","article-title":"Feasibility of brain atrophy measurement in clinical routine without prior standardization of the MRI protocol: Results from MS-MRIUS, a longitudinal observational, Multicenter real-world outcome study in patients with relapsing-remitting MS","volume":"39","author":"Zivadinov","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"116737","DOI":"10.1016\/J.NEUROIMAGE.2020.116737","article-title":"Brain volume loss in individuals over time: source of variance and limits of detectability","volume":"214","author":"Maranzano","year":"2020","journal-title":"NeuroImage"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2466\/PMS.1977.44.2.367;PAGE:STRING:ARTICLE\/CHAPTER","article-title":"Paced auditory serial addition task: a measure of recovery from concussion","volume":"44","author":"Gronwall","year":"1977","journal-title":"Percept Mot Skills"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/1352458509354552","article-title":"Psychometrics and normative data for the multiple sclerosis functional composite: replacing the PASAT with the symbol digit modalities test","volume":"16","author":"Drake","year":"2010","journal-title":"Mult Scler"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12883-015-0296-2\/FIGURES\/4","article-title":"A one-year follow-up study of the symbol digit modalities test (SDMT) and the paced auditory serial addition test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity","volume":"15","author":"L\u00f3pez-G\u00f3ngora","year":"2015","journal-title":"BMC Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/1352458513501570","article-title":"Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis","volume":"20","author":"Sonder","year":"2014","journal-title":"Mult Scler"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e2573","DOI":"10.1002\/BRB3.2573;PAGEGROUP:STRING:PUBLICATION","article-title":"Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates","volume":"12","author":"Rekik","year":"2022","journal-title":"Brain Behav"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1637835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:18:44Z","timestamp":1760588324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1637835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":65,"alternative-id":["10.3389\/fneur.2025.1637835"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1637835","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"article-number":"1637835"}}